Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Clopidogrel is frequently prescribed with aspirin for patients undergoing coronary artery bypass grafting (CABG).
• This practice extends to patients with stable coronary artery disease post-CABG.
• The evidence supporting this widespread use requires systematic evaluation.

Purpose of the Study:

• To systematically review published research on clopidogrel use after CABG.
• To assess the quality of trial data supporting clopidogrel's efficacy and safety in this patient population.
• To determine if clopidogrel provides a clear clinical benefit post-coronary artery bypass grafting.

Main Methods:

• Systematic review of studies reporting safety and/or efficacy data for clopidogrel with or without aspirin after on- or off-pump CABG.
• Inclusion of 14 studies: 11 reported trials and 3 ongoing trials.
• Analysis of subgroup retrospective data, surrogate endpoints, and observational cohort studies.

Main Results:

• Subgroup analyses of large trials did not demonstrate a clear clinical benefit of clopidogrel plus aspirin after CABG.
• A trend toward increased major and minor bleeding was observed with clopidogrel plus aspirin.
• Small prospective trials and studies on off-pump CABG lacked sufficient quality for definitive conclusions.

Conclusions:

• Current data from subgroup analyses, surrogate endpoints, and observational studies fail to establish a clear beneficial effect of clopidogrel on clinical outcomes post-CABG.
• The use of clopidogrel, alone or with aspirin, after CABG is not supported by robust evidence of clinical benefit.
• Further high-quality research may be needed to clarify the role of clopidogrel in post-CABG care, particularly regarding bleeding risks.